FDA.reportPublic FDA data

osimertinib 40 MG Oral Tablet [Tagrisso]

RxCUI
1721571
RxNorm name
osimertinib 40 MG Oral Tablet [Tagrisso]
Display name
osimertinib 40 MG Oral Tablet [Tagrisso]
Full name
osimertinib 40 MG Oral Tablet [Tagrisso]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:00

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
5e81b4a7-b971-45e1-9c31-29cea8c87ce7Tagrisso 40 MG Oral Tablet [PSN] · osimertinib 40 MG Oral Tablet [Tagrisso] [SBD] · Tagrisso 40 MG (as osimertinib mesylate 47.7 MG) Oral Tablet [SY]336These highlights do not include all the information needed to use TAGRISSO safely and effectively. See full prescribing information for TAGRISSO. TAGRISSO ® (osimertinib) tablets, for oral use Initial U.S. Approval: 201520240925